← All trials
NCT00005014
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 1997
- Primary completion
- —
- Completion date
- Feb 1, 2001
- First posted
- —
- Last posted
- —
- Enrollment
- 101
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Mental Health (NIMH)Lead sponsor
- University of California, Los AngelesOverall official - principal investigator
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Overall official - principal investigator
- Ohio State UniversityOverall official - principal investigator
- Yale UniversityOverall official - principal investigator
- Indiana UniversityOverall official - principal investigator
- National Institutes of Health (NIH)Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.